PDCD1 and hepatocellular carcinoma: In this prospective cohort study, we accordingly sought to characterize baseline circulating lymphocyte subsets and their changes in HCC patients treated with TACE administered with or without PD-1 inhibitors using high-dimensional flow cytometry and attempted to identify effective prognostic biomarkers.